Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912274 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Helsinn Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01912274 is a Phase 2 study that has completed, run by Helsinn Healthcare. The registered enrollment target is 50 participants.
The verdict
NCT01912274, a Phase 2 study, has completed, sponsored by Helsinn Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
Interventions
- DRUG Azacitidine
- DRUG Pracinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-12-24 |
| Est. Completion | 2016-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01912274
The ClinicalTrials.gov registry entry for NCT01912274 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Healthcare, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT01912274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01912274 about?
NCT01912274 is a clinical study titled "Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)". The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
What is the current status of trial NCT01912274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-12-24. Estimated completion is 2016-11-08.
What interventions are being tested in trial NCT01912274?
The interventions under investigation include: Azacitidine (DRUG), Pracinostat (DRUG).
Who is sponsoring clinical trial NCT01912274?
This trial is sponsored by Helsinn Healthcare, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.